Press Releases July 29, 2026 04:05 PM

Neostellar Capital Corp. to Report Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Neostellar Capital Corp. to Release Q2 2026 Financial Results on August 5, 2026 with Investor Conference Call

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
NSLR

Neostellar Capital Corp., a Nasdaq-listed investment firm specializing in venture-backed private companies, announced it will report its Q2 2026 financial results after market close on August 5, 2026. Management will host a conference call and webcast to discuss the results with investors.

Neostellar Capital Corp. to Report Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
NSLR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Neostellar invests in private, venture-backed companies, allowing public market investors exposure to private equity.
  • The company, formerly SuRo Capital Corp., has a 15-year track record in private company investment.
  • Management will provide Q2 2026 financial updates and engage investors via a conference call and webcast.

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Neostellar Capital Corp. ("Neostellar") (Nasdaq: NSLR), formerly SuRo Capital Corp., today announced that it will report its financial results for the quarter ended June 30, 2026 after the close of the U.S. market on Wednesday, August 5, 2026.

Management will hold a conference call and webcast for investors at 2:00 p.m. PT (5:00 p.m. ET). The conference call access number for U.S. participants is 833-492-0058, and the conference call access number for participants outside the U.S. is +1 973-528-0128. The conference ID number for both access numbers is 565747. Additionally, interested parties can listen to a live webcast of the call from the "Investor Relations" section of Neostellar Capital’s website at neostellar.vc. An archived replay of the webcast will also be available for 12 months following the live presentation.

A replay of the conference call may be accessed until 5:00 p.m. PT (8:00 p.m. ET) on August 12, 2026, by dialing 800-332-6854 (U.S.) or +1 973-528-0005 (International) and using conference ID number 565747.

About Neostellar Capital Corp.

Neostellar Capital Corp. (Nasdaq: NSLR), formerly SuRo Capital Corp. (Nasdaq: SSSS), has been a publicly traded investment company focused on investing in private, venture-backed businesses for over 15 years. In simple terms, Neostellar invests in companies that are not yet listed on a public stock exchange. By owning shares of Neostellar, investors can gain exposure to a portfolio of VC-backed companies through a publicly traded stock. Neostellar is externally managed by Neostellar Advisors LLC, a joint venture owned by certain Neostellar Advisor employees and Magnetar Holdings LLC. Together, the platform combines experience in private company investing with institutional investment management capabilities. Neostellar Capital Corp. is headquartered in New York, NY and has an office in San Francisco, CA. Connect with the Company on X, LinkedIn, and at neostellar.vc.

Contact

Neostellar Capital Corp.
(212) 931-6331
IR@neostellaradvisors.com


Risks

  • Financial results depend on performance of private, venture-backed portfolio companies which are subject to higher risk and volatility.
  • Market conditions affecting venture capital investments could impact Neostellar's valuation and future earnings.
  • Uncertainty around the company's earnings before official release creates potential stock price volatility around the earnings announcement.

More from Press Releases

FortuneX Acquisition Corporation and WT Realty Group Inc. Announce Business Combination Agreement Sep 18, 2026 XAI Floating Rate & Alternative Income Trust Announces Commencement of Tender Offer Sep 18, 2026 Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States Sep 18, 2026 Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking Sep 18, 2026 New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients Sep 18, 2026